Search

Your search keyword '"Falcone AP"' showing total 2 results
Start Over Author "Falcone AP" Topic antineoplastic agents
2 results on '"Falcone AP"'

1. Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase II, multi-arm, randomized UNITO-EMN10 trial.

Author

Mina R, Falcone AP, Bringhen S, Liberati AM, Pescosta N, Petrucci MT, Ciccone G, Capra A, Patriarca F, Rota-Scalabrini D, Bonello F, Musolino C, Cea M, Zambello R, Tacchetti P, Belotti A, Cellini C, Paris L, Grasso M, Aquino S, De Paoli L, De Sabbata G, Ballanti S, Offidani M, Boccadoro M, Monaco F, Corradini P, and Larocca A

Subjects
Aged, Aged, 80 and over, Antineoplastic Agents adverse effects, Antineoplastic Combined Chemotherapy Protocols adverse effects, Boron Compounds adverse effects, Female, Glycine adverse effects, Glycine therapeutic use, Humans, Induction Chemotherapy, Maintenance Chemotherapy, Male, Middle Aged, Treatment Outcome, Antineoplastic Agents therapeutic use, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Boron Compounds therapeutic use, Glycine analogs & derivatives, Multiple Myeloma drug therapy
Published
2021
Full Text
View/download PDF

2. Lenalidomide can induce long-term responses in patients with multiple myeloma relapsing after multiple chemotherapy lines, in particular after allogeneic transplant.

Author

Spina F, Montefusco V, Crippa C, Citro A, Sammassimo S, Olivero B, Gentili S, Galli M, Guglielmelli T, Rossi D, Falcone AP, Grasso M, Patriarca F, De Muro M, and Corradini P

Subjects
Adult, Aged, Aged, 80 and over, Cytogenetics, Dexamethasone administration & dosage, Dexamethasone therapeutic use, Humans, Immunoglobulin Isotypes immunology, Lenalidomide, Middle Aged, Multiple Myeloma drug therapy, Multiple Myeloma immunology, Multiple Myeloma mortality, Recurrence, Survival Analysis, Thalidomide therapeutic use, Time Factors, Transplantation, Homologous, Treatment Outcome, Antineoplastic Agents therapeutic use, Multiple Myeloma therapy, Stem Cell Transplantation, Thalidomide analogs & derivatives
Abstract

Evidence of long-term response to lenalidomide in heavily pretreated patients with multiple myeloma is lacking. This study sought to assess whether long-term responders exist, long-term responders' characteristics, and predictive factors of a long-term response. One hundred and four patients with multiple myeloma treated with lenalidomide and dexamethasone after ≥2 therapy lines (median, 3) were analyzed. Long-term response was defined as at least a partial response (≥PR) lasting ≥12 months. The overall response rate was 73%, and 80.3% of the responses were achieved within 5 months. The median response was 14.3 months. Patients evaluable for long-term response numbered 87, and a total of 47% were long-term responders. Compared to non-long-term responders, long-term responders had better overall survival, less light-chain multiple myeloma, and higher incidence of t(11;14). Previous allogeneic transplant (alloSCT) and the response quality predicted a long-term response. In conclusion, patients treated with lenalidomide can become long-term responders; alloSCT and response quality predict long-term response.

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results